Followers | 1077 |
Posts | 90220 |
Boards Moderated | 8 |
Alias Born | 07/26/2007 |
Tuesday, March 14, 2017 10:52:44 AM
http://ih.advfn.com/p.php?pid=nmona&article=74087311
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
Tonix Pharmaceuticals Holding (NASDAQ:TNXP)
Today : Tuesday 14 March 2017
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 14/214,433, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the proprietary sublingual formulation of TNX-102 SL*. A Notice of Allowance signifies that Tonix will be entitled to receive patent protection until 2034 in the U.S. for the allowed claims when the patent is issued. Tonix expects the patent to be issued within two months.
The allowed claims protect the pharmaceutical composition and the method of manufacturing of TNX-102 SL. The TNX-102 SL sublingual formulation is based on a eutectic between cyclobenzaprine HCl and mannitol, which protects the acidic hydrochloride salt of cyclobenzaprine from molecular interactions with the basic excipient, potassium phosphate dibasic, which is added to enhance transmucosal absorption. Transmucosal absorption of cyclobenzaprine increases the rate of absorption into the blood stream and bypasses first pass liver metabolism. TNX-102 SL is distinct from orally ingested forms of cyclobenzaprine, which are available as generic immediate-release tablets and branded extended-release capsules (AMRIX®), and are approved for short-term use (2-3 weeks) for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Since TNX-102 SL has a different route of administration and different pharmacokinetic profile from orally ingested cyclobenzaprine and is intended for a new indication (PTSD), pharmacists will not be able to substitute orally ingested forms of cyclobenzaprine for TNX-102 SL.
Tonix has filed trademarks to describe the protective eutectic, Protectic™, and the formulation that utilizes interactions at the angstrom scale, Angstro-Technology™. The Protectic™ protective eutectic and Angstro-Technology™ formulation enable TNX-102 SL to be a sublingual tablet of cyclobenzaprine HCl, while ensuring that the tablets have robust manufacturability and pharmaceutical stability.
Seth Lederman, M.D., president and chief executive officer of Tonix, stated, “This notice of allowance strengthens the value of our pipeline with near-term intellectual property protection and highlights Tonix’s innovation in proprietary pharmaceutical development. Most importantly, the Protectic™ protective eutectic and Angstro-Technology™ formulation are essential elements of the proprietary TNX-102 SL composition.”
*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
OTC-Killers-Club has spot 350 stock killers from 9000-Bagger to 2.2-bagger since 03/05/2011
Recent TNXP News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/20/2024 09:03:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 11:05:26 AM
- Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines • GlobeNewswire Inc. • 09/19/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 11:23:27 AM
- Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 11:05:24 AM
- Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:07:15 AM
- Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta • GlobeNewswire Inc. • 09/09/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 09:17:58 PM
- Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:08:17 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/30/2024 09:04:45 PM
- Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/29/2024 11:00:00 AM
- Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 11:05:17 AM
- Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801 • GlobeNewswire Inc. • 08/26/2024 11:00:00 AM
- Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 11:05:23 AM
- Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication • GlobeNewswire Inc. • 08/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 10:05:58 AM
- Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights • GlobeNewswire Inc. • 08/19/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/16/2024 09:18:38 PM
- Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency • GlobeNewswire Inc. • 08/16/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM